Skip to main content

UVA1 phototherapy for cutaneous diseases: an experience of 92 cases in the United States

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

Background:

The efficacy and safety of UVA1 (340–400 nm) phototherapy were established by studies from European countries. Purpose:

Evaluate experience with UVA1 phototherapy for patients with cutaneous diseases in the United States. Methods:

A retrospective analysis of 92 cases of UVA1-treated cutaneous conditions from four medical centers in the United States was performed. Results:

Two-third of the patients showed a fair to good response (26–100% improvement) and one-third of the patients showed a poor response (0–25% improvement). Diseases with a moderate to good response (51–100% improvement) included scleredema adultorum, hand or foot dermatitis, atopic dermatitis, morphea (medium or medium- to high-dose UVA1), systemic sclerosis, and urticaria pigmentosa. Besides tanning, other adverse effects were found in 15% of patients, which include pruritus, erythema, tenderness, and burning sensation. Patients with skin types I–III responded better that those with a darker skin type. Conclusion:

UVA1 phototherapy is a useful and well-tolerated treatment option for a variety of skin conditions.

Keywords: UVA1; phototherapy

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1600-0781.2006.00245.x

Affiliations: 1: Department of Dermatology, Henry Ford Hospital, Detroit, MI, USA, 2: Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA, 3: Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA and 4: Department of Dermatology, University of Alabama, Birmingham, AL, USA

Publication date: October 1, 2006

mksg/ppp/2006/00000022/00000005/art00004
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more